StockData
UNITED THERAPEUTICS Corp logo

UNITED THERAPEUTICS Corp (UTHR) stock

UTHRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 11/3025% above fair value
$591.17−2.14 (-0.36%)

Close on Nov 13, 2026Market cap $25.36BP/E 22.3Yield –

United Therapeutics operating margin

Operating margin is operating income as a percentage of revenue.

United Therapeutics's operating margin for the twelve months ending Sep 30, 2026 was 41.4%. For fiscal 2025 it was 46.9%, against 47.9% the year before. The highest annual figure on record is 66.4% in fiscal 2016.

Annual operating margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 202546.9%−1.0
FY2024Dec 31, 202447.9%−3.1
FY2023Dec 31, 202350.9%+0.3
FY2022Dec 31, 202250.6%+17.6
FY2021Dec 31, 202133.0%−7.0
FY2020Dec 31, 202040.0%+53.0
FY2019Dec 31, 2019-12.9%−62.4
FY2018Dec 31, 201849.5%+2.2
FY2017Dec 31, 201747.2%−19.2
FY2016Dec 31, 201666.4%+18.7
FY2015Dec 31, 201547.7%+5.9
FY2014Dec 31, 201441.8%+15.6
FY2013Dec 31, 201326.2%−19.8
FY2012Dec 31, 201246.0%+3.3
FY2011Dec 31, 201142.8%+13.9
FY2010Dec 31, 201028.9%+21.7
FY2009Dec 31, 20097.2%+36.3
FY2008Dec 31, 2008-29.1%–

Quarterly operating margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q3 FY2026Sep 30, 202637.0%−11.6
Q2 FY2026Jun 30, 202642.2%−3.4
Q1 FY2026Mar 31, 202641.7%−6.5
Q4 FY2025Dec 31, 202545.1%−3.5
Q3 FY2025Sep 30, 202548.6%+2.8
Q2 FY2025Jun 30, 202545.6%+0.9
Q1 FY2025Mar 31, 202548.2%−4.4
Q4 FY2024Dec 31, 202448.6%+6.3
Q3 FY2024Sep 30, 202445.8%−7.8
Q2 FY2024Jun 30, 202444.7%−7.8
Q1 FY2024Mar 31, 202452.6%−3.5
Q4 FY2023Dec 31, 202342.3%+6.6
Q3 FY2023Sep 30, 202353.7%−7.3
Q2 FY2023Jun 30, 202352.5%+9.3
Q1 FY2023Mar 31, 202356.1%−6.2
Q4 FY2022Dec 31, 202235.7%−5.2
Q3 FY2022Sep 30, 202260.9%+9.5
Q2 FY2022Jun 30, 202243.2%−6.5
Q1 FY2022Mar 31, 202262.4%+79.4
Q4 FY2021Dec 31, 202140.9%+23.9
Q3 FY2021Sep 30, 202151.4%−6.7
Q2 FY2021Jun 30, 202149.8%+11.0
Q1 FY2021Mar 31, 2021-17.1%−63.9
Q4 FY2020Dec 31, 202017.0%−3.4
Q3 FY2020Sep 30, 202058.2%+12.5
Q2 FY2020Jun 30, 202038.8%−20.4
Q1 FY2020Mar 31, 202046.8%+227.7
Q4 FY2019Dec 31, 201920.4%−14.1
Q3 FY2019Sep 30, 201945.7%+9.4
Q2 FY2019Jun 30, 201959.3%+10.4
Q1 FY2019Mar 31, 2019-180.9%−259.7
Q4 FY2018Dec 31, 201834.5%+4.6
Q3 FY2018Sep 30, 201836.2%−36.4
Q2 FY2018Jun 30, 201848.9%+29.0
Q1 FY2018Mar 31, 201878.9%+7.7
Q4 FY2017Dec 31, 201729.9%−12.7
Q3 FY2017Sep 30, 201772.7%–
Q2 FY2017Jun 30, 201719.9%–
Q1 FY2017Mar 31, 201771.1%–
Q4 FY2016Dec 31, 201642.6%–

More United Therapeutics figures

See a number that looks wrong?